Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PBLA Panbela Therapeutics Inc

-0.0191 (-3.68%)
Dec 05 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 126,804
Bid Price 0.50
Ask Price 0.5107
News -
Day High 0.5152


52 Week Range


Day Low 0.4919
Company Name Stock Ticker Symbol Market Type
Panbela Therapeutics Inc PBLA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0191 -3.68% 0.50 19:34:35
Open Price Low Price High Price Close Price Prev Close
0.505 0.4919 0.5152 0.5107 0.5191
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
500 126,804 $ 0.5071635 $ 64,310 - 0.48 - 295.20
Last Trade Time Type Quantity Stock Price Currency
19:34:35 formt 914 $ 0.50 USD

Panbela Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
17.69M 5.13M - 0 -34.93M -6.81 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Panbela Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No PBLA Message Board. Create One! See More Posts on PBLA Message Board See More Message Board Posts

Historical PBLA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.54210.650.49190.5131962745,381-0.0421-7.77%
1 Month0.87510.87510.480.5463285346,137-0.3751-42.86%
3 Months1.401.440.480.89361941,156,993-0.90-64.29%
6 Months5.929.040.481.581,050,134-5.42-91.55%
1 Year130.80295.200.4875.103,388,839-130.30-99.62%
3 Years4,200.0010,560.000.48269.631,283,365-4,199.50-99.99%
5 Years4,080.0010,560.000.48270.121,278,469-4,079.50-99.99%

Panbela Therapeutics Description

Panbela Therapeutics Inc is a clinical stage drug development company. It is engaged in the commercial development of a proprietary polyamine analogue for pancreatic cancer and for the second indication in chronic pancreatitis. The firm has developed a polyamine analogue compound referred as SBP-101 for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications.

Your Recent History

Delayed Upgrade Clock